CLINICAL TRIALS
A unique clinical trial
Heartland Herbal Healing Biotech holds a strategic stake in a clinical research initiative advancing innovative cannabis-based medicines for chronic pain management. The program operates under regulatory approval and represents a significant step toward validating cannabinoid therapies within modern healthcare.
This collaboration highlights the company’s commitment to clinical innovation, scientific credibility, and the development of evidence-based cannabinoid treatments for patients with unmet medical need.
Treating Chronic Pain
Millions of adults suffer from moderate to severe chronic pain, spanning conditions such as fibromyalgia and musculoskeletal disorders.
Heartland Herbal Healing Biotech is pioneering evidence-driven cannabinoid research to provide safer, more effective solutions for chronic pain, at a time when opioid-based therapies are increasingly challenged by limited outcomes and serious side effects.
PRIMARY END POINT
pain levels
Secondary end points
Stronger wellbeing, fewer opioids, better sleep, Less down time, more productive at work
Ground breaking medicine
This groundbreaking clinical program utilizes a leading precision inhalation device, integrated with a secure mobile application to capture real-time patient-reported outcomes and treatment data. The system delivers a controlled dose of pharmaceutical-grade medicinal cannabis at a pre-set temperature, ensuring accuracy, consistency, and physician-directed administration.
The cannabis formulation contained within each cartridge is produced under U.S. pharmaceutical -compliant manufacturing standards, ensuring purity, potency, and batch-to-batch consistency. Patients receive care under licensed U.S. medical professionals, with structured monitoring protocols and continuous clinical support to ensure safety, compliance, and optimized therapeutic outcomes.
Promising early results
Our initial testing phase has demonstrated consistent cannabinoid profiles and encouraging purity levels under controlled conditions. These early findings validate our approach toward scalable, pharmaceutical-grade production.
Preliminary process trials indicate strong potential for efficiency and repeatability in extraction methods. While still in development, these results support further optimization and scale-up.
Early formulation studies have shown stable compound behavior and consistency across controlled environments, reinforcing confidence in our product development direction.
Our initial validation efforts highlight a solid foundation in quality control and process design, positioning us well for future regulatory alignment and clinical readiness.
How to register
Living with non-cancer chronic pain? You may qualify for our monitored medical cannabis treatment program.